regulacija T-celic z dizajniranim transkripcijskim faktorjem NFAT
Špela Malenšek (Author), Roman Jerala (Mentor), Miha Pavšič (Thesis defence commission member), Gregor Gunčar (Thesis defence commission member), Janez Plavec (Co-mentor)

Abstract

Razvoj terapevtskih postopkov rakavih obolenj se zaradi kompleksnosti slednjih nagiba k usmerjenim in personaliziranim adaptivnim celičnim terapijam. Mednje sodijo celice CD19 CAR-T, pri čemer pacientovim limfocitom T vstavimo receptor CAR, specifičen za B-limfocitni antigen CD19. Terapija je uspešna pri B-celičnih malignih obolenjih, vendar so prisotni stranski učinki (SIRS, CRS) zaradi katerih je potrebno uravnavanje aktivnosti celic CAR-T. Z namenom regulacije celic CAR-T smo na osnovi transkripcijskega faktorja NFAT in heterodimerizacijskih domen ABI-PYL1, DmrA-DmrC in GAI-GID1 pripravili regulatorni sistem, ki celice aktivira ali represira. V celicah HEK293T in Jurkat smo potrdili, da ob dodatku ustreznih induktorjev (abscizinska kislina, rapamicin in giberelin) pride do heterodimerizacije konstruktov in da se NFAT učinkovito veže na vezavna mesta za DNA, pri čemer zanje tekmuje z endogenim NFAT. Hkrati smo pokazali, da heterodimerizacijski sistemi robustno aktivirajo celice Jurkat z receptorjem CD19-CAR ob prisotnosti celic, ki izražajo tarčni antigen (celice Raji).

Keywords

rakava obolenja;imunoterapija raka;adaptivni imunski odziv;celice CAR-T;heterodimerizacija;rapamicin;giberelin;abscizinska kislina;magistrska dela;

Data

Language: Slovenian
Year of publishing:
Typology: 2.09 - Master's Thesis
Organization: UL FKKT - Faculty of Chemistry and Chemical Technology
Publisher: [Š. Malenšek]
UDC: 577.27:616-006.6(043.2)
COBISS: 1538428355 Link will open in a new window
Views: 997
Downloads: 313
Average score: 0 (0 votes)
Metadata: JSON JSON-RDF JSON-LD TURTLE N-TRIPLES XML RDFA MICRODATA DC-XML DC-RDF RDF

Other data

Secondary language: English
Secondary title: Cancer immunotherapy: T-cell regulation via engineered transcription factor NFAT
Secondary abstract: In recent years, cancer immunotherapy has been leaning towards personalized, T-cell mediated therapy, due to the complex background of the disease. CD19 CAR-T cells represent a cure for hematologic malignancies. The therapy, albeit successful, does not avoid side effects such as SIRS and CRS and thus requires a development of a robust and reliable regulation of CAR-T cells. With CAR-T regulation in mind, we developed a regulatory system, based on transcription factor NFAT and heterodimerization domains ABI-PYL1, DmrA-DmrC, GAI-GID1, which either activates or represses the cells in question. We show that in the presence of chemical inductors (abscisic acid, rapamycin and gibberellin) the constructs undergo heterodimerization and that engineered NFAT, competing with endogenic NFAT, binds to its regulatory site of both reporter gene (shown in HEK293-T cells) or IL-2 (shown in Jurkat cells). We also confirm, that heterodimerization systems work in cells with expressed CD19-CAR and in presence of target antigen on the surface of Raji cells.
Secondary keywords: CAR-T;cancer immunotherapy;heterodimerization;rapamycin;gibberellin;abscisic acid;
Type (COBISS): Master's thesis/paper
Study programme: 1000377
Embargo end date (OpenAIRE): 1970-01-01
Thesis comment: Univ. v Ljubljani, Fak. za kemijo in kemijsko tehnologijo, smer Biokemija
Pages: 57 str.
ID: 11221180